Jump to content

Apocynin: Difference between revisions

Page 1
Page 2
Content deleted Content added
Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'UNII', 'ChEBI').
Citation bot (talk | contribs)
Altered bibcode. Add: authors 1-1. Removed URL that duplicated identifier. Removed parameters. Some additions/deletions were parameter name changes. | Use this bot. Report bugs. | Suggested by Neko-chan | #UCB_webform 149/440
 
(71 intermediate revisions by 42 users not shown)
Line 1: Line 1:
{{chembox
{{chembox
| Watchedfields = changed
| verifiedrevid = 413868642
| verifiedrevid = 443394610
| ImageFile=Acetovanillone.svg
| ImageFile1=Acetovanillone.svg
| ImageSize=150px
| ImageSize1=150px
| IUPACName=1-(4-Hydroxy-3-methoxyphenyl)ethanone
| ImageFile2=Apocynin-from-xtal-Mercury-3D-bs.png
| OtherNames=4-Hydroxy-3-methoxyacetophenone<br>Acetovanillone
| ImageSize2=200px
| Section1= {{Chembox Identifiers
| ImageFile3=Apocynin-from-xtal-Mercury-3D-sf.png
| ImageSize3=200px
| PIN = 1-(4-Hydroxy-3-methoxyphenyl)ethan-1-one
| OtherNames=1-(4-Hydroxy-3-methoxyphenyl)ethanone<br />4-Hydroxy-3-methoxyacetophenone<br />Acetovanillone
|Section1={{Chembox Identifiers
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = C11380
| KEGG = C11380
Line 21: Line 26:
| ChEMBL = 346919
| ChEMBL = 346919
| PubChem=2214
| PubChem=2214
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = B6J7B9UDTR
| UNII = B6J7B9UDTR
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 2781
| ChEBI = 2781
| SMILES = Oc1ccc(cc1OC)C(C)=O
| SMILES = Oc1ccc(cc1OC)C(C)=O
}}
}}
|Section2= {{Chembox Properties
|Section2={{Chembox Properties
| Formula=C<sub>9</sub>H<sub>10</sub>O<sub>3</sub>
| Formula = C<sub>9</sub>H<sub>10</sub>O<sub>3</sub>
| MolarMass=166.174
| MolarMass = 166.17 g/mol
| Appearance=
| Appearance=
| Density=
| Density=
| MeltingPtC=115
| MeltingPtC=115
| BoilingPtC= 295-300
| BoilingPt=
| Solubility=
| Solubility=
}}
}}
|Section3= {{Chembox Hazards
|Section3={{Chembox Hazards
| MainHazards=
| MainHazards=
| FlashPt=
| FlashPt=
| AutoignitionPt =
| Autoignition=
}}
}}
}}
}}
Line 44: Line 51:


== History ==
== History ==
Apocynin was first described by [[Oswald Schmiedeberg]], a German pharmacologist, in 1883 and was first isolated from the root of Canadian hemp (''Apocynum cannabinum''). At the time, this plant was already used for its known effectiveness against [[edema]] and heart problems. In 1971, apocynin was also isolated from ''Picrorhiza kurroa'', a small plant that grows at high altitudes in the western [[Himalayas]]. ''P. kurroa'' was used for ages as a treatment for liver and heart problems, [[jaundice]], and [[asthma]]. In 1990, Simons et al. isolated apocynin to a pharmacologically useful level using an actively guided isolation procedure. Apocynin’s observed anti-inflammatory capabilities proved to be a result of its ability to selectively prevent the formation of [[Radical (chemistry)|free radicals]], oxygen ions, and [[peroxide]]s in the body. Apocynin has since been extensively studied to help determine its disease-fighting capabilities and applications.
Apocynin was first described by [[Oswald Schmiedeberg]], a German pharmacologist, in 1883 and was first isolated by Horace Finnemore,<ref>{{cite book |title=Acetovanillone |url=https://books.google.com/books?id=zl3yCAAAQBAJ&pg=PA410 |pages=410–1 |isbn = 9783642649585|last1 = Paech|first1 = K.|last2 = Tracey|first2 = M. V.|date = 2012-12-06| publisher=Springer }} in {{cite book |first1=George |last1=de Stevens |first2=F. F. |last2=Nord |chapter=Natural Phenylpropane Derivatives |chapter-url=https://books.google.com/books?id=zl3yCAAAQBAJ&pg=PA392 |pages=392–427 |doi=10.1007/978-3-642-64958-5_10 |editor1-first=K. |editor1-last=Paech |editor2-first=M. V. |editor2-last=Tracey |year=1955 |title=Moderne Methoden der Pflanzenanalyse / Modern Methods of Plant Analysis |publisher=Springer-Verlag Berlin Heidelberg |isbn=978-3-642-64958-5 }}</ref> in 1908, from the root of Canadian hemp (''[[Apocynum cannabinum]]'').<ref>{{cite journal |last=Horace |first=Finnemore |title=The Constituents of Canadian Hemp. Part I. Apocynin |journal=Journal of the Chemical Society |year=1908 |volume=93 |issue=2 |pages=1513–9 |url=https://books.google.com/books?id=S982AAAAYAAJ&pg=PA1513 |access-date=10 April 2014 |doi=10.1039/ct9089301513 }}</ref> At the time, this plant was already used for its known effectiveness against [[edema]] and heart problems. In 1971, apocynin was also isolated from ''Picrorhiza kurroa'', a small plant that grows at high altitudes in the western [[Himalayas]]. ''P. kurroa'' was used for ages as a treatment for liver and heart problems, [[jaundice]], and [[asthma]]. In 1990, Simons et al. isolated apocynin to a pharmacologically useful level using an actively guided isolation procedure. Apocynin's observed anti-inflammatory capabilities proved to be a result of its ability to selectively prevent the formation of [[Radical (chemistry)|free radicals]], oxygen ions, and [[peroxide]]s in the body. Apocynin has since been extensively studied to help determine its disease-fighting capabilities and applications.{{citation needed|date=January 2016}}


== Physical properties ==
== Physical properties ==
Apocynin is a solid with a melting point of 115&nbsp;°C and the faint odor of [[vanilla]]. It is soluble in hot water, [[ethanol|alcohol]], [[benzene]], [[chloroform]], and [[diethyl ether|ether]].
Apocynin is a solid with a melting point of 115&nbsp;°C and the faint odor of [[vanilla]].<ref>{{Cite journal |last1=Stefanska |first1=J. |last2=Pawliczak |first2=R. |date=2008 |title=Apocynin: Molecular Aptitudes |journal=Mediators of Inflammation |volume=2008 |pages=106507 |doi=10.1155/2008/106507 |issn=0962-9351 |pmc=2593395 |pmid=19096513 |doi-access=free}}</ref> It is soluble in hot water,<ref>{{Cite web |title=Apocynin [498-02-2] Biotrend |url=https://www.biotrend.com/en/other-products-186/apocynin-498-02-2-231024630.html |access-date=2024-06-01 |website=www.biotrend.com}}</ref> [[ethanol|alcohol]], [[benzene]], [[chloroform]], [[DMSO]] and [[Dimethylformamide|DMF]].<ref>{{Cite web |title=498-02-2 Acetovanillone AKSci J20139 |url=https://aksci.com/item_detail.php?cat=J20139 |access-date=2024-06-01 |website=aksci.com}}</ref>


== Mode of action ==
== Mode of action ==
[[NADPH oxidase]] is an enzyme that effectively reduces O<sub>2</sub> to [[superoxide]] (O<sub>2</sub><sup>–•</sup>), which can be used by the immune system to kill bacteria and fungi. Apocynin is an inhibitor of NADPH oxidase activity and thus is effective in preventing the production of the superoxide in human white blood cells or neutrophilic [[granulocytes]]. It does not however obstruct the phagocytic or other defense roles of granulocytes. Due to the selectivity of its inhibition, apocynin can be widely used as an inhibitor of [[NADPH oxidase]] without interfering in other aspects of the immune system.
[[NADPH oxidase]] is an enzyme that effectively reduces O<sub>2</sub> to [[superoxide]] (O<sub>2</sub><sup>–•</sup>), which can be used by the immune system to kill bacteria and fungi. Apocynin is an inhibitor of NADPH oxidase activity and thus is effective in preventing the production of the superoxide in human [[Agranulocyte|agranulocytes]] or neutrophilic [[granulocyte]]s. It does not however obstruct the phagocytic or other defense roles of granulocytes. Due to the selectivity of its inhibition, apocynin can be widely used as an inhibitor of [[NADPH oxidase]] without interfering in other aspects of the immune system.<ref>{{Cite journal |last1=Barbieri |first1=Silvia S |last2=Cavalca |first2=Viviana |last3=Eligini |first3=Sonia |last4=Brambilla |first4=Marta |last5=Caiani |first5=Alessia |last6=Tremoli |first6=Elena |last7=Colli |first7=Susanna |title=Apocynin prevents cyclooxygenase 2 expression in human monocytes through NADPH oxidase and glutathione redox-dependent mechanisms |url=http://dx.doi.org/10.1016/j.freeradbiomed.2004.04.020 |journal=Free Radical Biology and Medicine |date=2004 |volume=37 |issue=2 |pages=156–165 |doi=10.1016/j.freeradbiomed.2004.04.020 |pmid=15203187 |issn=0891-5849}}</ref><ref>{{Cite journal |last1=Stolk |first1=J |last2=Hiltermann |first2=T J |last3=Dijkman |first3=J H |last4=Verhoeven |first4=A J |title=Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. |url=http://dx.doi.org/10.1165/ajrcmb.11.1.8018341 |journal=American Journal of Respiratory Cell and Molecular Biology |date=1994 |volume=11 |issue=1 |pages=95–102 |doi=10.1165/ajrcmb.11.1.8018341 |pmid=8018341 |issn=1044-1549}}</ref>


Apocynin was used to determine whether ionic activation due to proton flux across the membrane of renal medulla cells was coupled to NADPH oxidase production of superoxide. Apocynin was introduced to the cells and completely blocked the production of superoxide, and was a key component in determining that the proton outflow was responsible for the activation of NADPH oxidase.<ref>Li, N., Zhang, G., Yi, F.X., Zou, A.P., & Li, P.L. Activation of NAD(P)H oxidase by outward movements of H+ ions in renal medullary thick ascending limb of Henle. American Journal of Physiology-Renal Physiology 289.5 (2005): 1048–1056.</ref>
Apocynin was used to determine whether ionic activation due to proton flux across the membrane of renal medulla cells was coupled to NADPH oxidase production of superoxide. Apocynin was introduced to the cells and completely blocked the production of superoxide, and was a key component in determining that the proton outflow was responsible for the activation of NADPH oxidase.<ref>{{cite journal |vauthors=Li N, Zhang G, Yi FX, Zou AP, Li PL |title=Activation of NAD(P)H oxidase by outward movements of H+ ions in renal medullary thick ascending limb of Henle |journal=American Journal of Physiology. Renal Physiology |volume=289 |issue=5 |pages=F1048–56 |year=2005 |pmid=15972387 |doi=10.1152/ajprenal.00416.2004 |s2cid=25646988 }}</ref>


The mechanism of action of apocynin is not understood. In the experimental studies, apocynin is shown to dimerize and form [[diapocynin]].<ref>{{cite journal |last1=Luchtefeld |first1=Ron |last2=Dasari |first2=Mina S. |last3=Richards |first3=Kristy M. |last4=Alt |first4=Mikaela L. |last5=Crawford |first5=Clark F. P. |last6=Schleiden |first6=Amanda |last7=Ingram |first7=Jai |last8=Hamidou |first8=Abdel Aziz Amadou |last9=Williams |first9=Angela |last10=Chernovitz |first10=Patricia A. |last11=Sun |first11=Grace Y. |last12=Luo |first12=Rensheng |last13=Smith |first13=Robert E. |title=Synthesis of Diapocynin |journal=Journal of Chemical Education |volume=85 |issue=3 |year=2008 |pages=411 |bibcode=2008JChEd..85..411D |doi=10.1021/ed085p411 }}</ref> Although, diapocynin seems to have beneficial effect in reducing [[reactive oxygen species]] and anti-inflammatory properties, it is still yet to be shown as biologically relevant molecule.<ref>{{cite journal |vauthors=Chandasana H, Chhonker YS, Bala V, Prasad YD, Chaitanya TK, Sharma VL, Bhatta RS |title=Pharmacokinetic, bioavailability, metabolism and plasma protein binding evaluation of NADPH-oxidase inhibitor apocynin using LC-MS/MS |journal=Journal of Chromatography B |volume=985 |pages=180–8 |year=2015 |pmid=25682338 |doi=10.1016/j.jchromb.2015.01.025 }}</ref> Biotransformation of apocynin predominantly leads to glycosylated form of apocynin. Another molecule that is shown to form under experimental conditions is [[nitroapocynin]].<ref>{{cite journal |vauthors=Babu S, Raghavamenon AC, Fronczek FR, Uppu RM |title=4-Hydr-oxy-3-meth-oxy-5-nitro-aceto-phenone (5-nitro-apocynin) |journal=Acta Crystallographica E |volume=65 |issue=Pt 9 |pages=o2292–3 |year=2009 |pmid=21577684 |pmc=2969931 |doi=10.1107/S160053680903390X |bibcode=2009AcCrE..65o2292B }}</ref>
== Potential use in medical treatments ==

* Anti-arthritic: Neutrophils are a key component of the pathogenesis of collagen induced arthritis and in the mechanisms that lead to the start of inflammation of the joints. The action of apocynin reduces the presence of such cells before the inflammation has begun but it is unable to reverse inflammation that is already present.<ref>Hart, B.A., Simons, J.M ., Knaan–Shanzer, S., Bakker, N.P., & Labadie, R.P. Antiarthritic activity of the newly developed neutrophil oxidative burst antagonist apocynin. Free Radicals in Biology and Medicine 9.2 (1990): 127–131.</ref>
== Research ==
* Bowel disease: Apocynin treatment in rats has been proven to lessen damage in the colon as well as the enzymatic activity of myeloperoxidase which is associated with inflammation. In addition, apocynin also decreased the number of macrophages and polymorphonuclear leukocytes in the colon.<ref>Palmen M.J.H.J., Beukelman C.J., Mooij R.G.M., Pena A.S., & van Rees E.P. Anti-inflammatory effect of apocynin, a plant-derived NADPH oxidase antagonist, in acute experimental colitis. The Netherlands Journal of Medicine 47.2 (1995): 41–41.</ref>
{{medical citations needed|section|date=January 2017}}
* Anti-asthmatic: The glucoside of apocynin, androsen, is being investigated for the treatment of asthma for has been shown to prevent bronchial obstruction in guinea pigs. It is believed that the anti-asthmatic quality of apocynin comes from its interference with certain inflammatory processes.<ref>Van den Worm, E., Beukelman, CJ., Van den Berg, AJ., Kroes, BH., Labadie, RP., & Van Dijk, H. Effects of methoxylation of apocynin and analogs on the inhibition of reactive oxygen species production by stimulated human neutrophils. European Journal of Pharmacology 433.2 (2001): 225–230.</ref>
Small scale early stage clinical trials for apocynin were conducted for [[chronic obstructive pulmonary disease]] (COPD) in 2011<ref>{{ClinicalTrialsGov|NCT01402297|Hydrogen Peroxide and Nitrite Reduction in Exhaled Breath Condensate of COPD Patients}}</ref> and asthma in 2012<ref name=Stephanska2012>{{cite journal |vauthors=Stefanska J, Sarniak A, Wlodarczyk A, Sokolowska M, Pniewska E, Doniec Z, Nowak D, Pawliczak R |title=Apocynin reduces reactive oxygen species concentrations in exhaled breath condensate in asthmatics |journal=Experimental Lung Research |volume=38 |issue=2 |pages=90–9 |year=2012 |pmid=22296407 |doi=10.3109/01902148.2011.649823 |s2cid=207441506 }}</ref> but they did not progress any further.
* Atherosclerosis: Apocynin is used in the treatment of atherosclerosis in order to prevent the activity of NADPH oxidase activity, halting the production of reactive oxidative species. In effect, this inhibition stops initiation of disease in the endothelial cells.<ref>Peters, E.A., Hiltermann, J.T., & Stolk, J. Effects of methoxylation of apocynin and analogs on the inhibition of reactive oxygen species production by stimulated human neutrophils. Free Radicals in Biology and Medicine 31.11 (2001): 1442–1447.</ref>

* Familial ALS: Apocynin extended the lives of mutant mice and reduced [[glial cell]] toxicity of cultured cells lines with a defective Superoxide Dismutase-1 ([[SOD1]]) gene -- a genetic defect found in some people with hereditary [[amyotrophic lateral sclerosis]] (ALS, or Lou Gehrig's disease). Researchers believe the benefit derives from a newly discovered role for SOD1 as a self-regulating redox sensor for [[NADPH oxidase]]-derived O2• production. The findings in mice may point to new drug targets for hereditary ALS.<ref>Harraz, MM., Marden, JJ., Zhou1, W., Zhang, Y., Williams, A., Sharov, VS., Nelson, K., Luo, M., Paulson, H., Schöneich, C. and Engelhardt JF. [http://content.the-jci.org/articles/view/34060 SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model]. J. Clin. Invest. {{DOI|10.1172/JCI34060}}. Jan 24, 2008.</ref>
Other preliminary pre-clinical research includes:
* Anti-arthritic: Neutrophils are a key component of the pathogenesis of [[collagen-induced arthritis]] and in the mechanisms that lead to the start of inflammation of the joints. The action of apocynin reduces the presence of such cells before the inflammation has begun but it is unable to reverse inflammation that is already present.<ref name=Hart1990>{{cite journal |vauthors='T Hart BA, Simons JM, Knaan-Shanzer S, Bakker NP, Labadie RP |title=Antiarthritic activity of the newly developed neutrophil oxidative burst antagonist apocynin |journal=Free Radical Biology & Medicine |volume=9 |issue=2 |pages=127–31 |year=1990 |pmid=2172098 |id={{INIST|19326251}} |doi=10.1016/0891-5849(90)90115-Y }}</ref>
* Bowel disease: Apocynin treatment in rats has been proven to lessen damage in the colon as well as the enzymatic activity of myeloperoxidase which is associated with inflammation. In addition, apocynin also decreased the number of macrophages and polymorphonuclear leukocytes in the colon.<ref name=Palmen1995>{{cite journal |last1=Palmen |first1=M.J.H.J. |last2=Beukelman |first2=C.J. |last3=Mooij |first3=R.G.M. |last4=Pena A.S. |last5=van Rees |first5=E.P. |title=Anti-inflammatory effect of apocynin, a plant-derived NADPH oxidase antagonist, in acute experimental colitis |journal=The Netherlands Journal of Medicine |volume=47 |issue=2 |year=1995 |pages=41 |doi=10.1016/0300-2977(95)97051-P }}</ref>
* Anti-asthmatic: The glucoside of apocynin, [[androsen|androsin]], is being investigated for the treatment of asthma for has been shown to prevent bronchial obstruction in guinea pigs. It is believed that the anti-asthmatic quality of apocynin comes from its interference with certain inflammatory processes.<ref name=pmid11755156>{{cite journal |vauthors=Van den Worm E, Beukelman CJ, Van den Berg AJ, Kroes BH, Labadie RP, Van Dijk H |title=Effects of methoxylation of apocynin and analogs on the inhibition of reactive oxygen species production by stimulated human neutrophils |journal=European Journal of Pharmacology |volume=433 |issue=2–3 |pages=225–30 |year=2001 |pmid=11755156 |doi=10.1016/S0014-2999(01)01516-3 }}</ref>
* Atherosclerosis: Apocynin is used in the treatment of atherosclerosis in order to prevent the activity of NADPH oxidase activity, halting the production of reactive oxygen species. In effect, this inhibition stops initiation of disease in the endothelial cells.<ref name=pmid11755156/>
* Familial ALS: Apocynin extended the lives of mutant mice and reduced [[glial cell]] toxicity of cultured cells lines with a defective [[superoxide dismutase 1]] (SOD1) gene—a genetic defect found in some people with hereditary [[amyotrophic lateral sclerosis]] (ALS, or Lou Gehrig's disease). Researchers believe the benefit derives from a newly discovered role for SOD1 as a self-regulating redox sensor for [[NADPH oxidase]]-derived O2• production. The findings in mice may point to new drug targets for hereditary ALS.<ref>{{cite journal |vauthors=Harraz MM, Marden JJ, Zhou W, Zhang Y, Williams A, Sharov VS, Nelson K, Luo M, Paulson H, Schöneich C, Engelhardt JF |title=SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model |journal=The Journal of Clinical Investigation |volume=118 |issue=2 |pages=659–70 |year=2008 |pmid=18219391 |pmc=2213375 |doi=10.1172/JCI34060 }}</ref>

* Skin stem cells: Apocynin promotes the synthesis of collagen 17 and by doing this it increases the survival of the mother cells derived from stem cells.<ref>{{cite journal|vauthors=Liu N, Matsumura H, Kato T, Ichinose S, Takada A, Namiki T, Asakawa K, Morinaga H, Mohri Y, De Arcangelis A, Geroges-Labouesse E, Daisuke Nanba D, Nishimura EK |title=Stem cell competition orchestrates skin homeostasis and ageing |journal=Nature |volume= 568 |issue=7752 |pages=344–350 |year=2019 |doi= 10.1038/s41586-019-1085-7|pmid=30944469 |bibcode=2019Natur.568..344L |s2cid=92997308 }}</ref>


== References ==
== References ==
{{Reflist}}
{{Reflist}}


[[Category:Ketones]]
[[Category:O-methylated natural phenols]]
[[Category:Phenols]]
[[Category:Vanilloids]]
[[Category:Phenol ethers]]
[[Category:Aromatic ketones]]
[[Category:Catechols]]

[[de:Apocynin]]
[[ru:Апоцинин]]